ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 514

Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis

Katja Perdan-Pirkmajer1, Sergej Pirkmajer2, Alojzija Hocevar1, ŽIga Rotar1, Natasa Gaspersic1, Sonja Praprotnik1, Matija Tomsic3 and Ales Ambrozic1, 1Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, 2Institute of Pathophysiology, Faculty of Medicine Ljubljana, Ljubljana, Slovenia, 3Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, Ljubljana, Slovenia

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Diabetes, methotrexate (MTX), psoriatic arthritis and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose

Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) are associated with an increased risk of diabetes mellitus (DM). Disease-modifying anti-rheumatic drugs, including methotrexate (MTX), may exert protective metabolic effects conducive to reduced incidence of DM. Whether MTX mitigates metabolic risk factors in non-diabetic RA and PsA patients has not been determined unequivocally. In this study we assessed metabolic parameters in RA or PsA patients during the first six months of MTX therapy.

Methods

Newly diagnosed, MTX-naïve RA (2010 ACR/EULAR criteria) and PsA (CASPAR criteria) patients were included between December 2012 and June 2013. Patients with DM or hypothyroidism were excluded. The initial assessment included DAS28ESR, BMI, fasting plasma glucose and insulin, HbA1c, TSH, triglycerides, HDL, LDL and urate. Disease activity and the metabolic parameters were followed 1, 2, 3 and 6 months after MTX initiation. Uninterrupted MTX treatment with dose escalation according to the treat to target approach was required. HOMA-IR (glucose (mM) x insulin (μU/ml)/22.5), HOMA-B (20 x insulin (μU/ml)/[glucose (mM)-3.5]) and QUICKI ([log10glucose (mg/dl) + log10insulin (μU/ml)]-1) were used as surrogate indices of insulin sensitivity and β-cell function. ANOVA or the Kruskal-Wallis test, followed by an appropriate post hoctest was used to establish statistical significance.

Results

Inclusion criteria were fulfilled by 16 RA and 10 PsA patients (16 female, 10 male). Mean age was 52.5±12.2 (range: 27-76), BMI 28.4±4.8 kg/m2 (range: 19.7-39.4) and the initial DAS28ESR 5.23±1.27 (range: 2.95-7.71). Eighteen patients had prediabetes according to the American Diabetes Association criteria (HbA1c: 5.7-6.4%), while 11 patients had insulin resistance as assessed by HOMA-IR (>2.5). After six months of MTX (±methylprednisolone) therapy remission or low disease activity (DAS28ESR<3.2) was achieved in 76%. BMI, fasting plasma glucose, insulin, triglyceride, cholesterol or urate levels remained unaltered. Conversely, HbA1c (%) decreased in a time-dependent manner from the baseline value of 5.80±0.29% to 5.55±0.31% (n=26, P=0.017) at 6 months. HbA1c (%) was reduced in 17 out of 26 patients. The decrease in HbA1c (%) was especially pronounced in patients without insulin resistance at inclusion (5.82±0.35% vs. 5.42±0.32%, P=0.013, 12 out of 14 patients). Overall, the number of patients with prediabetes was reduced from 18 to 8. HOMA-IR, HOMA-B and QUICKI remained unaltered in patients receiving MTX or MTX and methylprednisolone, indicating co-therapy with methylprednisolone did not impair insulin sensitivity.

Conclusion

MTX reduces serum HbA1c in non-diabetic RA or PsA patients during the initial 6 months of treatment. As assessed by HbA1c MTX also reduces the prevalence of prediabetes, consistent with the notion that MTX protects against the development of DM. According to recent data HbA1c is not only an established predictor of CV risk in diabetic patients, but also an independent CV risk predictor in non-diabetics. Taken together, our findings support a possible role of MTX in reducing DM and CV risk in RA as well as PsA patients.


Disclosure:

K. Perdan-Pirkmajer,
None;

S. Pirkmajer,
None;

A. Hocevar,
None;

Rotar,
None;

N. Gaspersic,
None;

S. Praprotnik,
None;

M. Tomsic,
None;

A. Ambrozic,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/methotrexate-reduces-the-frequency-of-prediabetes-in-patients-with-rheumatoid-arthritis-or-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology